Brief: Ambu Q4 EBIT Before Items Loss DKK 7 Million, In Line With Expectations

Ambu A/S

15/11/2022 06:17

Nov 15 (Reuters) - Ambu A/S  AMBUb.CO :
    * Q4 REVENUE DKK 1,163M MILLION VERSUS DKK 1,159 MILLION
SEEN IN
COMPANY CONSENUS
    * Q4 EBIT BEFORE SPECIAL ITEMS LOSS DKK 7 M MILLION VERSUS
LOSS
DKK 7 MILLION SEEN IN COMPANY CONSENUS
    * WE LAUNCH AMBU'S NEW STRATEGY
    * ENDOSCOPY SOLUTIONS IN Q4 GREW ORGANICALLY BY 3% (37%),
WHILE
ANAESTHESIA AND PATIENT MONITORING (PM) POSTED ORGANIC GROWTH
RATES OF 0% (-6%) AND 10% (13%), RESPECTIVELY
    * FOR 2022/23, AMBU HAS SET FINANCIAL TARGETS: ORGANIC
REVENUE
GROWTH: 5-8%, EBIT MARGIN: 3-5%
    * ORGANIC REVENUE GROWTH FOR 2022/23 IS PROJECTED AT 5-8%,
WITH
HIGHEST GROWTH COMING FROM ENDOSCOPY SOLUTIONS
    * WE ASPIRE TO DELIVER LONG-TERM SUSTAINABLE DOUBLE-DIGIT
REVENUE
GROWTH
    * ENT AND CYSTOSCOPY BUSINESSES WILL CONTINUE TO DELIVER
DOUBLE-DIGIT GROWTH
    * TOTAL COMPANY GROWTH IS EXPECTED TO ACCELERATE
QUARTER-OVER-QUARTER THROUGH 2022/23, WHILE Q1 2022/23 IS
EXPECTED TO BE APPROXIMATELY FLAT VERSUS. Q1 2021/22
    * DUE TO HIGHER INPUT COSTS, MEXICO RAMP-UP AND PRODUCT MIX,
GROSS
MARGIN IS EXPECTED TO DECREASE BY ABOUT 2 PERCENTAGE POINTS IN
2022/23
    * EBIT MARGIN BEFORE SPECIAL ITEMS IS EXPECTED TO BE 3-5%
FOR
2022/23, WILL BE BACK-END LOADED DUE TO MORE SCALE IN OPEX
THROUGHOUT YEAR AS REVENUE WILL GROW
    * FY SALES OF ENDOSCOPES AT 1,705,000 UNITS VERSUS 1,676,263
UNITS
SEEN IN COMPANY CONSENUS
    * LAUNCHES ZOOM IN STRATEGY AIMED AT DELIVERING STRONG
PROFITABLE
GROWTH
    * ON ZOOM IN STRATEGY: TO DIRECT FOCUS TO INNOVATION OF
FEWER
HIGH-VALUE PROJECTS WITH DIRECT COMMERCIAL PRESENCE IN KEY
MARKETS
    * LONG TERM FINANCIAL TARGET: TO DELIVER LONG-TERM
SUSTAINABLE
DOUBLE-DIGIT REVENUE GROWTH WITH CONTINUOUSLY UPWARD TRENDING
EBIT MARGINS TO INDUSTRY  LEVELS

Source text for Eikon:  ID:nGNEbcFnhJ 
Further company coverage:  AMBUb.CO 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))